Pfizer ( PFE) reported fourth quarter and full-year 2024 earnings results Tuesday, narrowly beating Wall Street expectations ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Rezolute (RZLT – Research Report) and Pfizer (PFE – Research ...

Pfizer PFE announced positive top-line results from the progression-free survival (PFS) analysis of a late-stage study of its ...

Stocks are struggling for direction today, and one sector that represents this choppiness is blue-chip drugmakers. Merck & Co ...

Global pharmaceutical company Pfizer (NYSE:PFE) reported Q4 CY2024 results , with sales up 21.9% year on year to $17.76 ...

Pfizer (PFE) stock is up today after the pharmaceutical company reported earnings for the fourth quarter of 2024. The company ...

Pfizer posted Q4 revenue of $17.76 billion, up 22% YoY, with strong sales from Paxlovid, Vyndaqel, and Eliquis. The company reaffirmed its 2025 revenue outlook.

Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter and full-year 2024 and reaffirmed its 2025 financial guidance(5) provided on December 17, 2024. The ...

Pfizer’s adjusted fourth-quarter profit of 63 cents a share beat the FactSet consensus estimate of 47 cents a share. Revenue rose to $17.76 billion from $14.57 billion, and beat the FactSet consensus ...

Pfizer Inc. (NYSE: PFE) reported a strong performance for the fourth quarter of 2024, with revenues reaching $17.8 billion.

Pfizer expects full-year earnings in the range of $2.80 to $3 per share, with revenue in the range of $61 billion to $64 billion. This story was generated by Automated Insights ( ...